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S UMM A R Y
S E T T I NG : Eight tuberculosis treatment sites in Cavite
Province, the Philippines, including two sites specialising
in management of multidrug-resistant tuberculosis
(MDR-TB).
OB J E C T I V E : To evaluate costs incurred by TB patients
and to determine the proportion of households that
faced catastrophic costs, then to consider cost survey
responses alongside results of detailed patient-pathway
modelling.
DE S I GN : Clustered cross-sectional survey using a field
testing version of the WHO TB patient-costing tool and
protocol; face-to-face interviews with 194 patients
conducted in May–August 2016. Costs included direct-
medical, direct non-medical and indirect costs using the
human capital approach. Patients were deemed to incur
catastrophic expenditure if TB-related costs exceeded
20% of annual household income. Patient pathways
were modelled following multiple health staff inter-
views.
R E SU LT S : Estimated mean cost incurred by patients
with drug-susceptible TB was US$321 vs. $2356 for
MDR-TB patients. Catastrophic costs were suffered by
28% of drug-susceptible and 80% of MDR-TB patients,
with lost income being the largest contributor. Patient-
pathway modelling suggested most patients had under-
reported health visits.
CONC LU S I ON : Survey results indicate that patient costs
are large for all patients in Cavite, particularly for MDR-
TB patients. Patient-pathway modelling suggests these
costs are an underestimate due to poor recollection of
health visits, suggesting that the WHO instrument and
protocol could be improved to better capture the
diagnostic journey.
K E Y WORD S : health expenditures; computer simula-
tion; cost of illness; catastrophic costs
TUBERCULOSIS (TB) IS CLOSELY associated with
poverty: populations with few resources and poor
access to healthcare face the greatest burden.1
Although TB drugs are typically available to patients
without charge, patients often incur numerous costs
on the care pathway: direct out-of-pocket costs for
medical expenses, transport, temporary accommoda-
tion and food, and indirect costs due to lost income.
High patient costs place an immense burden on
household-finances,2 become an obstacle to accessing
treatment3 and are a factor in treatment non-
completion.4,5 When considering TB interventions,
an understanding of the size, origins and drivers of
these costs should be considered alongside other
evidence in decision-making.
Interest in patient costs and ‘catastrophic expendi-
ture’ for TB has grown in recent years.6–8 Along with
setting targets relating to TB incidence and deaths,
the WHO post-2015 Global TB Strategy (End TB
Strategy) set a third target of eliminating catastrophic
costs for TB-affected families by 2020,9 in line with
efforts to move health systems closer to universal
health coverage. Families are considered to incur
catastrophic expenditure if 20% or more of their
annual household income is spent on TB-related
costs.10 This 20% threshold aims to capture the point
at which households would forgo basic sustenance
expenditure. Research in Peru also found that this
threshold was associated with poor biomedical
outcomes from TB treatment.11
The 2016 Philippine National Prevalence Survey
(NPS) places the country fourth worldwide in terms
of TB incidence rates,12 with potentially one million
people living with active disease.13 Although Filipino
poverty is declining, 26.3% remain below the
national poverty line.14 Philippines is a high-burden
country for multidrug-resistant TB (MDR-TB), rep-
resenting 2.6% of new and 28% of previously treated
TB cases.15
Tupasi et al. found Filipino MDR-TB patients who
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were lost to follow-up (LTFU) had incurred signifi-
cantly higher travel costs to treatment facilities than
patients who completed treatment.5 Loss to follow-
up was also associated with lack of time to visit
facilities due to work/family commitments, and
individuals who were LTFU were significantly less
likely to have received food and transport assistance,
or medication for adverse drug reactions. Among the
long-term recommendations of the NPS is the
development of adequate social protection strate-
gies;16 however, successful implementation requires a
clearer understanding of the make-up of costs and
where they occur along the pathway.
STUDY SETTING AND CONTEXT
Cavite is one of Philippines’ most populous, fastest
growing and most industrialised provinces.17 Baran-
gay Health Workers (primary care) typically refer
presumptive drug-susceptible TB (DS-TB) cases to
local DOTS centres, and presumptive MDR-TB
patients to specialised Programmatic Management
of Drug-Resistant Tuberculosis centres (PMDT),
where they are treated as outpatients for 18–24
months. The standard tests at these centres are
respectively sputum smear microscopy (SSM) and
the XpertwMTB/RIF assay (Cepheid, Sunnyvale, CA,
USA). Smear-negative cases are typically diagnosed
clinically using chest X-ray (usually patient-funded),
and borderline cases diagnosed by a regularly
convened TB Diagnostic Committee (TBDC).
A patient-pathway initiative to identify potential
benefits of implementing new diagnostic strategies
has been developed for Cavite using the approach
previously developed for Tanzania, Brazil and South
Africa,18–20 but extended to include patient cost
impacts. This offers a unique opportunity to report
patient cost data collection and analyses alongside the
findings of patient-pathway modelling.
Study objectives
Study objectives were 1) to document the magnitude
and composition of TB patient-costs in Cavite; 2) to
determine the percentage of TB patients treated in the
National TB Programme (NTP) in Cavite who
incurred catastrophic costs; and 3) to consider
responses to the patient-cost survey alongside TB
patient-pathway modelling to enhance understanding
of financial barriers for TB patients.
METHODS
Study design
The study used a field testing version of the WHO TB
patient costing tool (November 2015) and protocol to
evaluate direct and indirect TB patient costs.10 The
refined instrument can be downloaded from the
WHO website.21 The field testing instrument differs
slightly from the current instrument and is available
on request from the authors in either Tagalog or
English. Data were collected through face-to-face
interviews with patients enrolled across eight treat-
ment sites in Cavite between May and August 2016.
Patient inclusion criteria were age 16 years, being
on treatment for pulmonary TB and current treat-
ment phase (intensive or continuation) being started
over 2 weeks previously.
Ethics
Ethical approval was granted by the Liverpool School
of Tropical Medicine Research Ethics Committee,
Liverpool, UK, and De La Salle Medical and Health
Sciences Institute’s Institutional Ethics Committee,
Cavite, The Philippines. Patients were read a disclo-
sure statement before agreeing to participation and
were given 300 Philippine pesos ($6.38) for their
time. Interviews were conducted in Tagalog.
Sample size
Calculations were based on 18% with catastrophic
costs and a relative precision of 40%.22 The sample
size calculated was 164, with 95% confidence
intervals, and design effect of 1.5, based on a
population of one million. Assuming a non-partici-
pation rate of 15%, we required a sample size of 194.
This was split across sites according to the number of
registered cases in 2015.
Estimating costs
For more details see Supplementary Tables S1–S3 and
WHO handbook10). TB treatment regimens have two
phases: intensive, followed by continuation. DS-TB
patients undergo 2 months of intensive phase
treatment, followed by 4 months of the continuation
phase; MDR-TB patients typically undergo respec-
tively 6 and 18 months. The WHO instrument is a
cross-sectional survey, with each participant inter-
viewed only once, answering patient cost questions
about their current phase. Assuming a consistent
frequency of trips and uniform expenditure within the
phase, costs were then scaled up to be representative
of the full phase-length. For example: for costs asked
about ‘so far in this phase’, if a patient was a third of
the way through the phase, costs were tripled.
Transport costs were similarly asked ‘per trip’ and
scaled to full phase.
Costs for the other phase (not currently experi-
enced by the patient) were estimated, based upon the
median costs in each category reported by patients in
their facility within that phase of their treatment (DS/
MDR). New patients in the intensive-phase were also
asked about pre-treatment health-seeking costs in-
curred before their registration within the NTP
network.
Because most patients were expected to be earning
informally,23 changes in regular income were difficult
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to accurately detect; our main analysis is therefore
based on the human capital approach for calculating
indirect costs. That is, each patient’s time lost due to
treatment was estimated and multiplied by their
hourly wage, as derived from their reported hours
worked and monthly earnings.
All patients were asked about ‘coping strategies’
their households had employed throughout treat-
ment. These included the selling of land/assets, taking
out of loans, any money borrowed, and if any
household member had prematurely left schooling.
Patients who indicated that they had a ‘guardian’
during treatment were asked whether this guardian
was a household member, and whether this guardian
lost an income when accompanying them; their lost
time was assumed to equal the patient’s, and valued at
the national minimum wage (378.5 PHP/day or
US$8.05/day).
Measuring household income
Self-reported household income prior to TB disease
was used. For patients who reported a household
income of zero, this was taken at face value, and
households subsequently considered to incur cata-
strophic costs.
Missing values
Missing values were replaced with median data field
values for other patients within the phase.
Sensitivity analyses
Sensitivity analyses were conducted on the human
capital vs. output method, wherein cost of lost time is
estimated through income change across time points,
and the catastrophic cost threshold.
Patient-pathway model
As part of a separate modelling study evaluating
potential diagnostic strategies for TB andMDR-TB in
Cavite, a detailed operational model has been built by
the authors, with full details to be published
elsewhere. This model was structured around the
journey (pathway) to diagnosis taken by patients
across the eight Cavite sites. Created using WITNESS
software,24 it was developed and populated with
evidence gathered from in-depth interviews with local
health system staff and additional data from site
logbooks and medical records, while patient cost
inputs were guided by the findings of this survey.
Within the present study, findings of this pathway
modelling have been compared with responses
collected using the WHO questionnaire, and the
discrepancies explored.
RESULTS
Demographics
Of the 195 patients invited to participate, only one
declined. Within the sample (Table 1), the mean age
was 41 years (standard deviation [SD] 16); 66% were
male; 58% were in work (81% of these informally);
71% had achieved a highest educational level no
higher than secondary school; 53% were in house-
holds where over two adults regularly slept (with
10% six plus). The mean number of children per
household was 1.6.
TB status within sample
Overall, 169 patients were on DS-TB treatment and
25 on MDR-TB treatment (Table 2); 30% were
retreatment patients (MDR-TB, 24 [96%]; DS-TB, 33
[20%]), and 12% currently had another household
member on treatment; 42% of patients were inter-
viewed in the intensive phase and 58% in the
continuation phase.
Table 1 Participant demographic data
Attributes Category n %
All patients 194 100
Sex Male 129 66
Female 65 34
Patient age group, years 15–19 11 6
20–29 49 25
30–39 35 18
40–49 35 18
50–59 30 15
60–69 26 13
70 8 4
Type of employment Unemployed 78 40
Formal paid work 21 11
Informal paid work 91 47
Retired 3 2
Housework 1 1
Highest educational level attained
by patient
Primary school 39 20
Secondary school 99 51
University 42 22
Graduate school 9 5
Other 5 3
Highest educational level attained
by head of household
Did not attend school 5 3
Primary school 41 21
Secondary school 90 46
University 11 6
Graduate school 36 19
Other 11 6
How many adults regularly sleep
in your house?
1 18 9
2 74 38
3 40 21
4 25 13
5 17 9
6þ 20 10
How many children* regularly
sleep in your house?
0 56 29
1 47 24
2 41 21
3 26 13
4 16 8
5þ 8 4
How many rooms in your house
excluding the bathroom?
0 4 2
1 78 40
2 76 39
3 27 14
4 8 4
5 1 1
*No age limit given; could potentially have been misinterpreted as children of
any age.
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Household income
The mean household annual income (Table 3) was
PHP169 635, equal to $3610 ($1 ¼ PHP46.99, July
201625), with a SD PHP209 123 ($4450); 55% were
earning below the poverty line of PHP131 628
(PHP10 969 or $233 monthly). Nine patients (5%)
reported zero household income.
Pre-diagnosis
Pre-diagnostic patient-costs made up 9.4% of total
DS-TB patient costs, and 4.7% of total MDR-TB
patient costs. For both DS and MDR-TB patients,
these costs primarily came from direct medical costs,
but also included travel and lost income. However,
31% recalled only one trip for DS-TB diagnosis
(including trip for results of diagnostic tests) with
another 31% stating two trips (mean 2.4). For MDR-
TB patients, the mean was 2.5 trips (Table 4). For
trips reported during treatment see Supplementary
Data, Table S4).
Patient costs
A total of 33% of patients had paid for travel for their
most recent follow-up visit (mean cost $1.09; maxi-
mum cost $9.53 (Figure 1 and Supplementary Data
Table 2 TB-specific participant data
Attributes Category n %
TB diagnosis and treatment site
All patients 194 100
Drug-susceptible TB 169 87
Dasmarin˜as City Health Office 43 22
Imus 21 11
Silang Canossa 10 5
Tanza 48 25
Trece Martires 34 18
Tagaytay 13 7
MDR-TB 25 13
PMDT La Salle 15 8
General Aguinaldo Memorial Hospital 4 2
Imus 2 1
Tanza 4 2
Previously treated? Yes, retreatment 57 29
No, new 137 71
Bacteriologically confirmed? Bacteriologically confirmed 102 53
Clinically diagnosed 92 47
Treatment phase Intensive 82 42
Continuation 112 58
Treatment facility type Public health centre 163 84
Public hospital 5 3
NGO hospital 10 5
Private clinic 14 7
Other 1 1
How many other members of your
household are receiving treatment
for TB?
0 170 88
1 17 9
2 3 2
3 2 1
4 1 1
5 1 1
TB ¼ tuberculosis; MDR-TB ¼ multidrug-resistant TB; PMDT ¼ Programmatic Management of Drug-Resistant
Tuberculosis; NGO¼ non-governmental organisation.
Table 3 Household income before contracting TB*
Annual household
income pre-TB
(PHP)
(upper bound
in US$) n %
Cumulative
%
0 0 9 4.6 4.6
1–19999 426 10 5.2 9.8
20000–39999 851 11 5.7 15.5
40000–59999 1277 8 4.1 19.6
60000–79999 1702 30 15.5 35.1
80000–99999 2128 20 10.3 45.4
100000–149999 3192 32 16.5 61.9
150000–199999 4256 25 12.9 74.7
200000–299999 6384 24 12.4 87.1
300000–399999 8512 13 6.7 93.8
400000 12 6.2 100.0
Total 194 100
*Annual income bracketed in Philippine pesos (PHP) (1US$ ’ 46.99 PHP).
TB¼ tuberculosis.
Table 4 Number of trips to a health centre before treatment
initiation that patients were able to recall and provide costs for
Number of trips
to a health centre
before treatment
initiation
Drug-susceptible TB MDR-TB
n %
Cumulative
% n %
Cumulative
%
1 15 31 31 1 8 8
2 15 31 62 7 53 61
3 10 20 82 3 23 84
4 6 12 94 2 15 100
5 2 4 98 0 0 100
6 1 2 100 0 0 100
Mean number
of trips 2.4 2.5
MDR-TB¼multidrug-resistant tuberculosis.
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Table S5). Only four patients (2%) had accommoda-
tion costs for their last follow-up visit; 4% of patients
had paid radiography costs in their most recent follow-
up appointment, while only 1% had paid for other
tests. Overall, 73% reported spending money on
nutritional supplements outside their regular diet, with
similar likelihood across MDR-TB and DS-TB pa-
tients. The mean extra weekly spend on nutrition for
DS-TB patients was $4.61 during the intensive, and
$4.23 during the continuation phase, rising to $5.33
and $5.61 for MDR-TB patients. When scaled to full
treatment length, these costs become considerable,
estimated at $98 for DS-TB patients and $344 for
MDR-TB patients. Although not powered to analyse
between-site differences, the study found variability,
including average transport costs 10x larger in
Tagaytay than Tanza ($112 vs. $11), likely due to
the rural landscape. The proportion incurring cata-
strophic costs (DS-TB only) ranged from 4.8% (Imus)
to 38.5% (Tagaytay).
Guardian accompaniment
Overall, 32% of MDR-TB patients and 42% of DS-
TB patients answered that they had a ‘guardian’;
however only nine people indicated this guardian lost
income, included within the indirect costs in Figure 1.
Financial assistance and insurance
Few patients had insurance other than the Department
of Health’s national insurance plan Philhealth.26 Of
MDR-TB patients, 76% reported receiving goods or
vouchers, whereas only 12% for DS-TB patients.
Social impact and coping
Overall, 7% of patients had sold assets due to illness,
including mobile phones, animals, household items
and employment-specific construction equipment;
37% had used savings to cover costs, with mean
spend $145; 36% had borrowed money (mean $112),
with 70% expected to pay this back; 46% lost a job,
while 26% reported social exclusion. Furthermore,
19% reported facing food insecurity and 6% had seen
a household member interrupt schooling. Two
patients (1%) reported separating/divorcing due to
their illness.
Catastrophic costs
Overall, 28% of DS-TB patients and 80% of MDR-
TB patients suffered catastrophic costs. Across
categories, average costs were generally higher for
patients facing catastrophic costs. For DS-TB pa-
tients, direct medical costs are almost three times
larger for patients who were catastrophic. The largest
contributor to costs for all groups are indirect costs,
being particularly severe for MDR-TB patients facing
catastrophic costs (60% of costs) (See also Figure 2
and Supplementary Data Table S5).
Sensitivity analysis
The Output method for lost-income was separately
calculated, giving much higher indirect and total
costs: $470 for DS-TB patients and $4660 for MDR-
TB (vs. $321 and $2356 above) (Supplementary Data
Table S5). With a threshold as low as 10%, there
would be 58% of families deemed to be facing
catastrophic costs with the human capital approach
(62% using the output approach).With a threshold of
50%, 20% of households incurred catastrophic costs
(Supplementary Data Figure S1).
Patient-pathway modelling
Patient-pathway modelling revealed that across all six
Figure 1 Total cost breakdown showing relative proportions between (all) MDR-TB and DS-TB
patients. Note: the areas of the charts are proportional with respect to costs. MDR-TB¼multidrug-
resistant tuberculosis; DS-TB¼ drug-susceptible TB.
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DOTS sites, patients must make a minimum of four
trips to receive a diagnosis for DS-TB, increasing to
seven for smear-negative patients who do not have a
recent chest X-ray. This would be attained at the
hospital at a patient’s expense. Figure 3 shows a
simplified patient-pathway for an example DS-TB
site (Tanza).
DISCUSSION
In Cavite, 80% of MDR-TB and 28% of DS-TB
patient households faced catastrophic costs. Further-
more, our parallel pathway modelling suggests that
this is likely an underestimate of the true scale.
Patient-costs were greater for MDR-TB patients
than DS-TB patients, the largest cost-component
being lost-income (59% and 41%, respectively).
Those without catastrophic expenditure had lost a
smaller proportion of income, suggesting that reduc-
ing or reimbursing income-loss could reduce the
likelihood of costs becoming catastrophic. Evidence
suggests this could be achieved through targeted
social-protection schemes;27 however, currently in
Philippines such schemes are limited. While someone
in formal employment could receive sick-pay for TB
(up to 2 months for MDR-TB) e.g., SSS, GSIS,28,29
formal employment is rare among our sample (only
11%) where most are employed informally. None of
the 11% working formally reported receiving sick
pay. The poorest may also have been eligible for the
Bridging Program for the Filipino Family (‘4Ps’)
conditional cash-transfer programme,30 although
currently access is limited. Nevertheless, with in-
creased political drive there is scope for broadening
and strengthening such policies. Furthermore, indi-
rect-costs for MDR-TB patients may soon see
considerable reductions, with encouraging recent
evidence regarding shorter 9-month treatment regi-
mens for MDR-TB.31 It is noteworthy that six (24%)
of our MDR-TB patients answered they had not
received vouchers or goods during treatment, despite
policy being that MDR-TB patients should have
received $2/day during treatment, plus $95 after 6
and 12 months, and $191 at completion.32 Partici-
pants were not asked why, but this may have been due
to lack of ‘full adherence’.33
Medical expenditure, while only a small part of
MDR-TB patient-costs, made up 20% (and with a
Figure 2 Patient cost breakdown split by whether or not patients incurred catastrophic costs. The two bars on the left hand side
show for DS-TB patients, while the bars on the right show for MDR-TB patients. DS-TB¼ drug-susceptible TB; MDR-TB¼multidrug-
resistant tuberculosis.
Figure 3 Drug-susceptible TB patient pathway for Tanza, the Philippines (morning-spot collection site) showing minimum number of
patient trips required to obtain diagnosis (red arrows). CXR¼ chest X-ray; sm neg¼ smear-negative; sm pos¼ smear-positive.
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larger absolute value) for DS-TB patients. This is
principally due to high hospitalisation costs being
covered by the PMDT for MDR-TB patients. Travel
was a considerably larger component of MDR-TB
costs, due to more centre visits, indicating scope for
reducing costs through transportation interventions
or decentralising some MDR-TB appointments to
reduce travel distances.
Nutritional supplement costs were notably high,
increasing in patients with catastrophic expenditure,
and making up almost a third of all costs for DS-TB
patients, despite a lack of evidence supporting their
effectiveness.34 Improved nutritional information
with less emphasis on expensive supplements may
help reduce these costs and should be investigated.
Overall reported medical expenses were lower than
our patient-pathway modelling expected. For pre-
diagnostic costs, only half (16/31) of CD patients
stated any radiography costs, while the number of
trips reported in attaining TB diagnoses was consid-
erably lower than the pathway suggests. 31% of DS-
TB patients reported a single trip, however pathway-
modelling showed a minimum of four trips required.
In all sites smear-negative patients would be required
to return with an X-ray, however the mean number of
reported trips did not differ between SM-/þ patients.
This suggests that interviews inadequately elicited
pre-diagnostic information – whether due to recall
bias or some other mechanism - likely leading to
overall underreporting of costs. Furthermore, by
asking patients about most recent visits (and with a
2-week minimum treatment requirement for survey
participation), it is possible that medical expenses
early in the treatment phase were missed.
We acknowledge limitations in the study instru-
ment and the study design. The length of the WHO
instrument frequently caused patient fatigue, while
the shifting time-frames used throughout the ques-
tionnaire (e.g., ‘. . .most recent visit’, ‘. . .over the last
week’, ‘. . .since the start of this phase’, ‘since the start
of treatment’) may have caused confusion. Both
factors could have impacted data quality. Addition-
ally, the cross-sectional design requires numerous
simplifying assumptions in scaling-up values. While it
is conceivable that expenditure would vary over the
course of treatment, the extrapolation method is
insensitive to such changes. Furthermore, coping
mechanisms are not scaled-up under the design, and
so certainly provide an underestimate.
CONCLUSION
Patient costs in Cavite are high, and many patients are
suffering from catastrophic expenditure. The WHO
questionnaire—here and worldwide—likely underes-
timates the true extent of such costs, due to its cross-
sectional design and errors in inducing accurate
patient recall. It would be valuable to compare
longitudinal study results from a similar population
to explore this further. The present evidence suggests
the challenge of achieving zero catastrophic costs in
Cavite requires interventions and resources to address
lost income and costs incurred purchasing nutritional
supplements. Since differing expenditures afflict
patients with varying severity, targeted initiatives
are required to mitigate or recompense these costs, so
that TB-affected households can be safeguarded from
the spiral of impoverishment and disease.
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R E´ S U M E´
CONT EX T E : Huit sites de traitement de la tuberculose
(TB) dans la province de Cavite, Philippines, dont deux
sites spe´cialise´s en prise en charge de la TB
multire´sistante (MDR-TB).
OB J E C T I F : Evaluer les couˆts incombant aux patients
tuberculeux et de´terminer la proportion de foyers qui
ont subi des couˆts catastrophiques, puis conside´rer les
re´ponses a` l’enqueˆte de couˆt paralle`lement aux re´sultats
de la mode´lisation de´taille´e du parcours des patients.
S CH E´MA : Enqueˆte transversale en grappes base´e sur
une version adapte´e au terrain du de l’outil et le
protocole de l’Organisation mondiale de la Sante´
(OMS) d’e´valuation des couˆts ; des entretiens face a`
face avec 194 patients re´alise´s entre mai et aouˆt 2016.
Les couˆts ont inclus les de´penses directes me´dicales,
directes non me´dicales et indirectes graˆce a` l’approche
du capital humain. Les patients ont e´te´ invite´s a` exposer
des de´penses catastrophiques si celles lie´es a` la
tuberculose exce´daient 20% des revenus annuels du
foyer. Les parcours des patients ont e´te´ mode´lise´s apre`s
de multiples entretiens avec le personnel de sante´.
R E´ S U LTAT S : Le couˆt moyen estime´ pour les patients
atteints de tuberculose pharmacosensible a e´te´ de
321$US et pour les patients atteints de MDR-TB, de
2356 $US. Les couˆts catastrophiques ont concerne´ 28%
des patients pharmacosensibles et 80% des patients
MDR-TB, la perte de revenus y contribuant le plus. La
mode´lisation du parcours des patients a sugge´re´ que la
majorite´ des patients avaient sous de´clare´ leurs
consultations.
CONC LU S I ON : Les re´sultats de l’enqueˆte montrent que
les couˆts sont importants pour tous les patients de
Cavite, particulie`rement les patients MDR-TB. La
mode´lisation du parcours des patients a sugge´re´ que
ces couˆts e´taient sous-estime´s en raison d’une me´diocre
me´morisation des consultations, sugge´rant que
l’instrument de l’OMS et le protocole pouvaient eˆtre
ame´liore´s afin de mieux saisir le parcours diagnostique.
R E S UM E N
MARCO DE R E F E R ENC I A: Ocho centros de tratamiento
de la tuberculosis (TB) en la Provincia de Cavite de
Filipinas, incluidos dos centros especializados en el
tratamiento de la TB multirresistente (MDR-TB).
O B J E T I V O S: Evaluar los costos asumidos por los
pacientes con TB, determinar la proporcio´n de hogares
que afrontan «costos catastro´ficos» y analizar luego las
respuestas a la encuesta sobre costos, al mismo tiempo
que los resultados de una modelizacio´n detallada de la
trayectoria de los pacientes hasta obtener el diagno´stico.
M E´ T O D O: Se realizo´ un estudio transversal en
conglomerados con una versio´n de ensayo sobre el
terreno de la herramienta y el protocolo de la
Organizacio´n Mundial de la Salud (OMS) de
evaluacio´n de los costos para los pacientes a causa de
la TB; se llevaron a cabo entrevistas presenciales a 194
pacientes de mayo a agosto del 2016. Se analizaron los
costos me´dicos directos, los costos directos no me´dicos y
los costos indirectos con el me´todo de capital humano.
Se considero´ que los pacientes asumı´an gastos
catastro´ficos cuando los gastos relacionados con la TB
excedı´an 20% del ingreso familiar anual. La trayectoria
de los pacientes se modelizo´ a partir de entrevistas
mu´ltiples a los profesionales de salud.
R E SU LTADOS: La estimacio´n del costo promedio para
los pacientes con TB normosensible fue 321 USD y para
los pacientes con MDR-TB fue 2356 USD. La TB
normosensible genero´ costos catastro´ficos en 28% de los
pacientes y la MDR-TB en 80% de los casos y la
principal razo´n fue la pe´rdida de ingresos. La
modelizacio´n de la trayectoria diagno´stica indico´ que
la mayorı´a de los pacientes habı´a subestimado el nu´mero
de consultas por salud.
CONC LU S I O´ N: Los resultados del estudio indican que
los costos son considerables para todos los pacientes en
Cavite, sobre todo los pacientes con MDR-TB. La
modelizacio´n de la trayectoria de los pacientes revela
una subestimacio´n de estos costos debido a una memoria
deficiente de las consultas me´dicas, lo cual sen˜ala la
posibilidad de mejorar la herramienta y el protocolo de
la OMS para que capte mejor los datos sobre el recorrido
del paciente hasta obtener el diagno´stico.
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